NewAmsterdam Pharma Co N.V. (NAMS) insider trading

By person

17 insiders · 0 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

NAP B.V. ForGrowth

10% owner

—

10,656,172

$266.72M

−9.9%

James N Topper

Director

—

3,028,524

$75.80M

+0.7%

Michael H. Davidson

Chief Executive Officer

—

1,078,638

$27.00M

+31.8%

Johannes Jacob Pieter Kastelein

Chief Scientific Officer

—

192,104

$4.81M

+177.2%

Mayur Ian Somaiya

Chief Financial Officer

—

58,382

$1.46M

—

Michael F Marino III

See Remarks

—

55,000

$1.38M

—

Douglas F Kling

Chief Operating Officer

—

44,000

$1.10M

—

William A Jones Jr

Chief Commercial Officer

—

43,000

$1.08M

—

Louise Frederika Kooij

Chief Accounting Officer

—

24,353

$609.56K

—

Juliette Berangere Audet

See Remarks

—

15,104

$378.05K

+1,268%

Adele M. Gulfo

Director

—

14,260

$356.93K

—

William Lewis

Director

—

10,360

$259.31K

—

Mark C. McKenna

Director

—

10,360

$259.31K

—

Louis G Lange

Director

—

10,360

$259.31K

−58.4%

der Kamp Hilde Johanna van

Director

—

10,360

$259.31K

—

John W Smither

Director

—

8,760

$219.26K

—

Robert William Gunning

Vice President, Controller

—

3,200

$80.10K

—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

NewAmsterdam Pharma Co N.V.

What the insiders did No buying or selling

By person